Results 121 to 130 of about 22,314 (175)

Targeting the Menin–KMT2A interaction in leukemia: Lessons learned and future directions

International Journal of Cancer, Volume 158, Issue 2, Page 342-356, 15 January 2026.
Abstract Chromosomal rearrangements involving the Mixed Lineage Leukemia gene (MLL1, KMT2A) are defining a genetically distinct subset in about 10% of human acute leukemias. Translocations involving the KMT2A‐locus at chromosome 11q23 are resulting in the formation of a chimeric oncogene, where the N‐terminal part of KMT2A is fused to a variety of ...
Florian Perner, Jayant Y. Gadrey, Scott A. Armstrong, Michael W. M. Kühn   +3 more
wiley   +1 more source

The role of azacitidine in the management of myelodysplastic syndromes (MDS)

Cancer Management and Research, 2009
KS Götze, C Müller-Thomas, C PeschelDepartment of Medicine, Hematology/Oncology, Technische Universität München, Munich, GermanyAbstract: Myelodysplastic syndromes (MDS) are a group of common bone marrow disorders ...
KS Götze, C Müller-Thomas, C Peschel   +2 more
doaj  

Therapeutic targeting of chromatin alterations in leukemia and solid tumors

International Journal of Cancer, Volume 158, Issue 2, Page 382-408, 15 January 2026.
Abstract Alterations in chromatin conformation and post‐translational modification of histones have become increasingly recognized as critical drivers of cancer development, progression, and therapy resistance. Recent advances in drug development have led to the establishment of several highly selective small molecule inhibitors, several of which are ...
Florian Perner, Tobias Berg, Daniel Sasca, Sophie‐Luise Mersiowsky, Jayant Y. Gadrey, Johanna Thomas, Michael W. M. Kühn, Michael Lübbert   +7 more
wiley   +1 more source

Efficacy of 5-hydroxytryptamine 3 receptor antagonists versus metoclopramide for preventing nausea and vomiting during azacitidine chemotherapy in patients with myelodysplastic syndromes or acute leukemia: a retrospective observational study

Journal of Pharmaceutical Health Care and Sciences
Background 5-Hydroxytryptamine 3 receptor antagonists (5-HT3RAs) and dexamethasone are recommended to prevent azacitidine-induced nausea and vomiting. In clinical practice, 5-HT3RAs or metoclopramide is often used without dexamethasone. In this study, we
Yoshinori Wakasugi, Yoshito Ikeda, Satoshi Noda, Makoto Murata, Shin-ya Morita   +4 more
doaj   +1 more source

Azacitidine followed by R-GDP in transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma: preliminary results from a multicenter, phase II study

Therapeutic Advances in Hematology
Background: Epigenetic priming prior to chemotherapy represents a promising treatment strategy for refractory or relapsed diffuse large B-cell lymphoma (R/R DLBCL).
Dong Hyun Kim, Jee Hyun Kong, Junshik Hong, Ja Min Byun, Dong-Yeop Shin, Youngil Koh, Inho Kim, Jinny Park, Young Rok Do, Jeong-A Kim, Won Seog Kim, Ho-Jin Shin, Sung-Soo Yoon   +12 more
doaj   +1 more source

Loss of response to azacitidine is associated with deletion 12p13 in a patient with myelodysplastic syndrome with unique translocation t(13;17)(q12;q25) after prior breast cancer and acute promyelocytic leukemia [PDF]

, 2015
Jakšić, Ozren, Kušec, Rajko, Lasan-Trčić, Ružica, Lucijanić, Marko, Pejša, Vlatko, Štoos-Veić, Tajana   +5 more
core   +1 more source

Phase 1 results of ZUMA-1: A multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma [PDF]

, 2017
Bartlett, Nancy L, et al,, Ghobadi, Armin   +2 more
core   +2 more sources

Genome Agnostic Reprogramming of Acute Myelocytic Leukemia Hallmarks by Targeting Non-Oncogene Addictions with Azacitidine Plus Pioglitazone and All-Trans Retinoic Acid. [PDF]

Int J Mol Sci
Harrer DC, Lüke F, Pukrop T, Reichle A, Heudobler D.   +4 more
europepmc   +1 more source

Molecularly targeted therapy and immunotherapy in leukemias. [PDF]

J Hematol Oncol
Cousin E, Picard A, Oundjian M, Tardif N, Quemener A, Rio AG, Galibert MD, Gandemer V, Mazurier F.   +8 more
europepmc   +1 more source

XPO1 inhibitor selinexor enhances the apoptotic effect of azacitidine in T-cell lymphoma with TET2/RHOA mutations via JAK3/STAT3 axis. [PDF]

Cell Commun Signal
Xu TT, Cai MC, Cheng S, Huang YH, Zhang QQ, Xu PP, Wang L, Qiu YR, Zhao WL.   +8 more
europepmc   +1 more source